Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

D W Langdon, M P Amato, J Boringa, B Brochet, F Foley, S Fredrikson, P Hämäläinen, H-P Hartung, L Krupp, I K Penner, A T Reder, R H B Benedict, D W Langdon, M P Amato, J Boringa, B Brochet, F Foley, S Fredrikson, P Hämäläinen, H-P Hartung, L Krupp, I K Penner, A T Reder, R H B Benedict

Abstract

Background: Cognitive impairment in MS impacts negatively on many patients at all disease stages and in all subtypes. Full clinical cognitive assessment is expensive, requiring expert staff and special equipment. Test versions and normative data are not available for all languages and cultures.

Objective: To recommend a brief cognitive assessment for multiple sclerosis (MS) that is optimized for small centers, with one or few staff members, who may not have neuropsychological training and constructed to maximize international use.

Methods: An expert committee of twelve members representing the main cultural groups that have so far contributed considerable data about MS cognitive dysfunction was convened. Following exhaustive literature review, peer-reviewed articles were selected to cover a broad spectrum of cultures and scales that targeted cognitive domains vulnerable to MS. Each was rated by two committee members and candidates scales were rated on psychometric qualities (reliability, validity, and sensitivity), international application, ease of administration, feasibility in the specified context, and acceptability to patients.

Results: The committee recommended the Symbol Digit Modalities Test, if only 5 minutes was available, with the addition of the California Verbal Learning Test - Second Edition and the Brief Visuospatial Memory Test - Revised learning trials if a further 10 minutes could be allocated for testing.

Conclusions: A brief cognitive assessment for MS has been recommended. A validation protocol has been prepared for language groups and validation studies have commenced.

Conflict of interest statement

Professor Langdon has received funding for travel to scientific meetings from Bayer Healthcare; serves on a Steering Committee for Bayer Healthcare; has served/serves as a consultant to Merck-Serono, Bayer Healthcare; served on speaker bureau for Bayer Healthcare, Roche, Serono Symposia, TEVA Germany; receives research contract funding from Bayer Healthcare; receives educational grants from Bayer Healthcare.

Professor Amato received personal compensation from Merck Serono, Biogen Dompè, Sanofi Aventis, Bayer Schering for serving on scientific advisory board and for speaking. Professor Amato received financial support for research activities from Merck Serono, Sanofi Aventis, Biogen Dompè, Bayer Schering.

Dr Boringa has consulted for Bayer Healthcare served on speaker bureau for Exencia Pharma Academy.

Dr Brochet serves on scientific advisory boards for Bayer Schering Pharma, Novartis, and Merck Serono; has received funding for travel and speaker honoraria from Bayer Schering Pharma, Merck Serono, Biogen Idec, AB Sciences, and Teva Pharmaceutical Industries Ltd./Sanofi-Aventis; and serves as LEN editor for SEP et Neurosciences.

Dr Foley has received honoraria for speaking at scientific and patient-education meetings, serving on scientific advisory boards and consulting activities from Bayer–Schering, Biogen, and Teva Neuroscience.

Dr Fredrikson has received honoraria for lectures, educational activities and consultancy from Bayer, Biogen Idec and Sanofi–Aventis during the past year.

Dr Hämäläinen received personal compensation from Bayer Healthcare and Novartis for serving on scientific advisory boards; consulting for Sanofi–Aventis; served on speaker bureau for Bayer Healthcare and Sanofi–Aventis.

Professor Hartung received honoraria with approval by the Rector of Heinrich-Heine-University from Bayer Healthcare GmbH, Octapharma GmbH, Novartis, Teva Sanofi Aventis, Biogen Idec GmbH and Merck Serono GmBH for consulting and speaking at scientific symposia.

Dr Krupp has served on speaker bureaux, scientific advisory boards and/or been a consultant for Teva Neurosciences, BiogenIdec, EMD Serono, Multiple Sclerosis Association of America, Betaseron/Bayer Healthcare Pharmaceuticals, Pfizer, Sanofi–Aventis, Axon Advisors; she has received royalties from Genzyme, ER Squibb & Sons, NMSS, Novartis, MedImmune, Abbott Laboratories, Johnson&Johnson, Roche, Health Professions Conferencing Corp.

Dr Penner has received honoraria for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from Bayer–Schering, Biogen, Merck Serono, Roche, Novartis.

Dr Reder has recently submitted two articles to Neurology and his disclosures remain the same.

Professor Benedict has acted as a consultant or scientific advisory board member for Bayer, Biogen Idec, Merk Serono, EMD Serono, Pfizer, Novartis; royalties from Psychological Assessment Resources, Inc; financial support for research activities from Shire Pharmaceuticals, Biogen Idec.

Figures

Figure 1.
Figure 1.
Example of stimuli of the SDMT type.
Figure 2.
Figure 2.
Example stimuli of the CVLT-II type.
Figure 3.
Figure 3.
Example test stimuli of the BVMT-R type.

References

    1. Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol 2011; 24: 244–249
    1. Amato MP, Portaccio E, Goretti B, et al. Relevance of cognitive deterioration in early relapsing–remitting MS: a 3-year follow-up study. Mult Scler 2010; 16: 1474–1482
    1. Amato MP, Portaccio E, Stromillo ML, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology 2008; 71: 632–638
    1. Filippi M, Rocca MA, Benedict RH, et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology 2010; 75: 2121–2128
    1. Langdon D. Cognitive impairment in multiple sclerosis – recent advances and future prospects. Eur Neurol Rev 2010; 5: 69–72
    1. Strober L, Englert J, Munschauer F, et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult Scler 2009; 15: 1077–1084
    1. Sumowski JF, Wylie GR, Chiaravalloti N, DeLuca J. Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis. Neurology 2010; 74: 1942–1945
    1. Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology 2010; 24: 573–580
    1. Sherman TE, Rapport LJ, Ryan KA. Awareness of deficit in multiple sclerosis. J Clin Exp Neuropsychol 2008; 30: 301–311
    1. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. The Clinical Neuropsychologist 2002; 16: 381–397
    1. Sicotte NL. Neuroimaging in multiple sclerosis: neurotherapeutic implications. Neurotherapeutics 2011; 8: 54–62
    1. Cheng EM, Crandall CJ, Bever CT, et al. Quality indicators for multiple sclerosis. Mult Scler 2010; 16: 970–980
    1. Rao SM, the Cognitive Function Study Group of the National Multiple Sclerosis Society A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. Milwaukee, WI: Medical College of Wisconsin; 1990
    1. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler 2007; 13: 1176–1182
    1. Aupperle RL, Beatty WW, Shelton Fde N, Gontkovsky ST. Three screening batteries to detect cognitive impairment in multiple sclerosis. Mult Scler 2002; 8: 382–389
    1. Langdon D, Amato M, Boringa J, et al. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): first consensus steps towards a brief universal cognitive assessment for MS. Neurology 2011; 76: A479
    1. Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? CNS Drugs 2008; 22: 87–97
    1. Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF. Cognitive impairments in relapsing–remitting multiple sclerosis: a meta-analysis. Mult Scler 2008; 14: 1250–1261
    1. Smith A. Symbol Digit Modalities Test (SDMT) Manual (revised). Los Angeles: Western Psychological Services; 1982
    1. Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 2010; 16: 228–237
    1. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol 2000; 48: 885–92
    1. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987–997
    1. Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006; 12: 549–558
    1. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RH. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler 2007; 13: 52–57
    1. Holmén C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011; 17: 708–719
    1. Deloire MS, Bonnet MC, Salort E, et al. How to detect cognitive dysfunction at early stages of multiple sclerosis? Mult Scler 2006; 12: 445–452
    1. Portaccio E, Goretti B, Zipoli V, et al. Reliability, practice effects, and change indices for Rao’s Brief Repeatable Battery. Mult Scler 2010; 16: 611–617
    1. Camp SJ, Stevenson VL, Thompson AJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 1999; 122: 1341–1348
    1. Benedict RH, Duquin JA, Jurgensen S, et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 2008; 14: 940–946
    1. Morrow SA, Drake A, Zivadinov R, Munschauer F, Weinstock-Guttman B, Benedict RH. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. The Clinical Neuropsychologist 2010; 24: 1131–1145
    1. Bomboi G, Ikonomidou VN, Pellegrini S, et al. Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis. J Neuroimag 2011Apr; 21(2): e57–63 (Epub 2011 April).
    1. Houtchens MK, Benedict RH, Kiliiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 18: 1213–1223
    1. Brochet B, Deloire MS, Bonnet M, et al. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler 2008; 14: 1242–1249
    1. Mike A, Glanz BI, Hildenbrand P, et al. Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. AJNR Am J Neuroradiol 2011; 32: 515–521
    1. Stankiewicz JM, Glanz BI, Healy BC, et al. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimag 2011. April; 21(2): e50–6 (Epub 2011 April).
    1. Camp SJ, Stevenson VL, Thompson AJ, et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain 2005; 128: 2891–2898
    1. Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol, Neurosurg Psychiat 2009; 80: 201–206
    1. Warlop NP, Achten E, Fieremans E, Debruyne J, Vingerhoets G. Transverse diffusivity of cerebral parenchyma predicts visual tracking performance in relapsing–remitting multiple sclerosis. Brain and Cognition 2009; 71: 410–415
    1. Einarsson U, Gottberg K, von Koch L, et al. Cognitive and motor function in people with multiple sclerosis in Stockholm County. Mult Scler 2006; 12: 340–353
    1. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test, second edition (CVLT-II). San Antonio, TX: Psychological Corporation; 2000
    1. Stegan S, Stepanov I, Cookfair D, et al. Validity of the California Verbal Learning Test-II in multiple sclerosis. The Clinical Neuropsychologist 2010; 24: 189–202
    1. Fink F, Eling P, Rischkau E, et al. The association between California Verbal Learning Test performance and fibre impairment in multiple sclerosis: evidence from diffusion tensor imaging. Mult Scler 2010; 16: 332–341
    1. Sartori E, Edan G. Assessment of cognitive dysfunction in multiple sclerosis. J Neurol Sci 2006; 245: 169–175
    1. Benedict RH, Bakshi R, Simon JH, Priore R, Miller C, Munschauer F. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J Neuropsych Clin Neurosci 2002; 14: 44–51
    1. Benedict RHB. The Brief Visuospatial Memory Test Revised (BVMT-R). Lutz, FL: Psychosocial Assessment Resources Inc; 1997
    1. Rozewicz L, Langdon DW, Davie CA, Ron MA, Thompson AJ. Reversible focal cognitive impairment in multiple sclerosis. Cognitive Neuropsychiatry 1996; 1: 17–25
    1. Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S. Effect of high-dose cortisol on memory functions. Ann NY Acad Sci 2006; 1071: 434–437
    1. Smith MM, Arnett PA. Dysarthria predicts poorer performance on cognitive tasks requiring a speeded oral response in an MS population. J Clin Exp Neuropsychol 2007; 29: 804–812
    1. Bruce JM, Bruce AS, Arnett PA. Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. J Int Neuropsychol Soc 2007; 13: 544–548
    1. Boringa JB, Lazeron RH, Reuling IE, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler 2001; 7: 263–267
    1. Amato MP, Portaccio E, Goretti B, et al. The Rao’s Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler 2006; 12: 787–793
    1. Oken BS, Flegal K, Zajdel D, et al. Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity. J Rehab Res Dev 2006; 43: 83–90
    1. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Int J Clin Prac 2009; 63: 1085–1094
    1. Dario A, Pisani R, Sangiorgi S, Pessina F, Tomei G. Relationship between intrathecal baclofen and the central nervous system. Acta Neurochir 2007; 97(Suppl.): 461–464
    1. Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 2011; 25: 89–107
    1. Ghaffar O, Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 2008; 71: 164–169
    1. Rabinowitz AR, Arnett PA. A longitudinal analysis of cognitive dysfunction, coping, and depression in multiple sclerosis. Neuropsychology 2009; 23: 581–591
    1. Benedict RH, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler 2004; 10: 675–678
    1. Krupp LB, Serafin DJ, Christodoulou C. Multiple sclerosis-associated fatigue. Expert Rev Neurother 2010; 10: 1437–1447
    1. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-beta 1b trial in multiple scelrosis: design and lessons from a 16-year observational study. Clin Therap 2009; 31: 1724–1736

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren